Exploring recent advances in signaling pathways and hallmarks of uveal melanoma: a comprehensive review

Majid Banimohammad , Parsa Khalafi , Danial Gholamin , Zahra Bangaleh , Nahid Akhtar , Abhishikt David Solomon , Pranav Kumar Prabhakar , Samira Sanami , Ajit Prakash , Hamidreza Pazoki-Toroudi

Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) : 1002306

PDF (2842KB)
Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) :1002306 DOI: 10.37349/etat.2025.1002306
Review
research-article
Exploring recent advances in signaling pathways and hallmarks of uveal melanoma: a comprehensive review
Author information +
History +
PDF (2842KB)

Abstract

The purpose of this review was to provide a comprehensive review of the latest insights on the pathogenesis of uveal melanoma (UM) and its intracellular pathways. This article covers the epidemiology of UM, racial predispositions, cytogenetic and chromosomal alterations, gene mutations, key defective pathways, and their underlying mechanisms, as well as the application of hallmarks of cancer to UM. A key knowledge gap remains in identifying the most effective targeted therapy and determining the central pathway linking multiple signaling networks. UM is a malignant tumor arising from uveal melanocytes, predominantly affecting the choroid, with both genetic and epigenetic contributors. Key cytogenetic alterations include monosomy 3, chromosome 6p gain, chromosome 1p loss, and chromosome 8q gain. The most important UM-related signaling pathways are RAS/MAPK, PI3K/Akt/mTOR, Hippo-YAP, retinoblastoma (Rb), and p53 pathways. In the RAS/MAPK pathway, GNAQ/GNA11 mutations occur which account for more than 80% of UM cases. The PI3K/Akt/mTOR pathway promotes cyclin D1 overexpression and MDM2 upregulation, leading to p53 pathway inhibition. GNAQ/GNA11 mutations activate YAP via the Trio-RhoGTPase/RhoA/Rac1 signaling circuit in the Hippo-YAP pathway. Rb pathway dysregulation results from cyclin D1 overexpression or cyclin-dependent kinase inhibitor (CDKI) inactivation. In the p53 pathway, UM is characterized by p53 mutations, MDM2 overexpression, and Bcl-2 deregulation. Eventually, the ARF-MDM2 axis serves as a critical link between the RAS and p53 pathways. Hallmarks of cancer, such as evasion of growth suppression and self-sufficiency in growth signals, are also evident in UM. Genetic and epigenetic alterations, including NSB1, MDM2 and CCND1 amplification, and BAP1 mutations, play pivotal roles in UM pathobiology. Thus, UM exhibits a multifactorial pathology. By consolidating key mechanisms underlying UM pathogenesis, this review provides a comprehensive perspective on the involved pathways, offering insights that may facilitate the development of effective therapeutic strategies.

Keywords

Uveal melanoma / rat sarcoma virus (RAS) pathway / Akt pathway / Hippo pathway / retinoblastoma (Rb) pathway / p53 pathway / hallmarks of cancer

Cite this article

Download citation ▾
Majid Banimohammad, Parsa Khalafi, Danial Gholamin, Zahra Bangaleh, Nahid Akhtar, Abhishikt David Solomon, Pranav Kumar Prabhakar, Samira Sanami, Ajit Prakash, Hamidreza Pazoki-Toroudi. Exploring recent advances in signaling pathways and hallmarks of uveal melanoma: a comprehensive review. Exploration of Targeted Anti-tumor Therapy, 2025, 6 (1) : 1002306 DOI:10.37349/etat.2025.1002306

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Beasley AB, Chen FK, Isaacs TW, Gray ES. Future perspectives of uveal melanoma blood based biomarkers. Br J Cancer. 2022; 126: 1511-28.

[2]

Krantz BA, Dave N, Komatsubara KM, Marr BP, Carvajal RD. Uveal melanoma: epidemiology, etiology, and treatment of primary disease. Clin Ophthalmol. 2017; 11: 279-89.

[3]

Fu Y, Xiao W, Mao Y. Recent Advances and Challenges in Uveal Melanoma Immunotherapy. Cancers (Basel). 2022; 14: 3094.

[4]

Yang J, Manson DK, Marr BP, Carvajal RD. Treatment of uveal melanoma: where are we now? Ther Adv Med Oncol. 2018; 10: 1758834018757175.

[5]

Gelmi MC, Jager MJ. Uveal melanoma: Current evidence on prognosis, treatment and potential developments. Asia Pac J Ophthalmol (Phila). 2024; 13: 100060.

[6]

Fernandez MF, Choi J, Sosman J. New Approaches to Targeted Therapy in Melanoma. Cancers (Basel). 2023; 15: 3224.

[7]

Yu H, Fang D, Kumar SM, Li L, Nguyen TK, Acs G, et al. Isolation of a novel population of multipotent adult stem cells from human hair follicles. Am J Pathol. 2006; 168: 1879-88.

[8]

Vidács DL, Veréb Z, Bozó R, Flink LB, Polyánka H, Németh IB, et al. Phenotypic plasticity of melanocytes derived from human adult skin. Pigment Cell Melanoma Res. 2022; 35: 38-51.

[9]

Damato BE, Coupland SE. Ocular melanoma. Saudi J Ophthalmol. 2012; 26: 137-44.

[10]

Nayman T, Bostan C, Logan P, Burnier MN Jr. Uveal Melanoma Risk Factors: A Systematic Review of Meta-Analyses. Curr Eye Res. 2017; 42: 1085-93.

[11]

Thomsen H, Chattopadhyay S, Hoffmann P, Nöthen MM, Kalirai H, Coupland SE, et al. Genome-wide study on uveal melanoma patients finds association to DNA repair gene TDP1. Melanoma Res. 2020; 30: 166-72.

[12]

Broggi G, Russo A, Reibaldi M, Russo D, Varricchio S, Bonfiglio V, et al. Histopathology and Genetic Biomarkers of Choroidal Melanoma. Appl Sci. 2020; 10: 8081.

[13]

Amaro A, Gangemi R, Piaggio F, Angelini G, Barisione G, Ferrini S, et al. The biology of uveal melanoma. Cancer Metastasis Rev. 2017; 36: 109-40.

[14]

Hamadeh F, Medina CA, Singh AD, Reynolds JP, Biscotti CV. Uveal melanoma: An analysis of cellular features and comparison to monosomy 3 status. Diagn Cytopathol. 2016; 44: 377-83.

[15]

Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW. Immunohistochemical characteristics of melanoma. J Cutan Pathol. 2008; 35: 433-44.

[16]

Coupland SE, Lake SL, Zeschnigk M, Damato BE. Molecular pathology of uveal melanoma. Eye (Lond). 2013; 27: 230-42.

[17]

Luo H, Ma C. Identification of prognostic genes in uveal melanoma microenvironment. PLoS One. 2020; 15: e0242263.

[18]

Damato B, Dopierala JA, Coupland SE. Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification. Clin Cancer Res. 2010; 16: 6083-92.

[19]

Katopodis P, Khalifa MS, Anikin V. Molecular characteristics of uveal melanoma and intraocular tumors. Oncol Lett. 2021; 21: 9.

[20]

Helgadottir H, Höiom V. The genetics of uveal melanoma: current insights. Appl Clin Genet. 2016; 9: 147-55.

[21]

Johansson P, Aoude LG, Wadt K, Glasson WJ, Warrier SK, Hewitt AW, et al. Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4. Oncotarget. 2016; 7: 4624-31.

[22]

Moore AR, Ceraudo E, Sher JJ, Guan Y, Shoushtari AN, Chang MT, et al. Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. Nat Genet. 2016; 48: 675-80.

[23]

Slater K, Hoo PS, Buckley AM, Piulats JM, Villanueva A, Portela A, et al. Evaluation of oncogenic cysteinyl leukotriene receptor 2 as a therapeutic target for uveal melanoma. Cancer Metastasis Rev. 2018; 37: 335-45.

[24]

Habibi Z, Hoormand M, Banimohammad M, Ajami M, Amin G, Amin M, et al. The Novel Role of Crocus sativus L. in Enhancing Skin Flap Survival by Affecting Apoptosis Independent of mTOR: A Data-Virtualized Study. Aesthetic Plast Surg. 2022; 46: 3047-62.

[25]

Caunt CJ, Sale MJ, Smith PD, Cook SJ. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat Rev Cancer. 2015; 15: 577-92.

[26]

Tetsu O, McCormick F. ETS-targeted therapy: can it substitute for MEK inhibitors? Clin Transl Med. 2017; 6: 16.

[27]

Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y, Hu LL. ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med. 2020; 19: 1997-2007.

[28]

Park JJ, Diefenbach RJ, Joshua AM, Kefford RF, Carlino MS, Rizos H. Oncogenic signaling in uveal melanoma. Pigment Cell Melanoma Res. 2018; 31: 661-72.

[29]

Ma J, Weng L, Bastian BC, Chen X. Functional characterization of uveal melanoma oncogenes. Oncogene. 2021; 40: 806-20.

[30]

Neelature Sriramareddy S, Smalley KSM. MEK-ing the Most of It: Strategies to Co-target Gαq and MAPK in Uveal Melanoma. Clin Cancer Res. 2021; 27: 1217-9.

[31]

Sharma A, Stei MM, Fröhlich H, Holz FG, Loeffler KU, Herwig-Carl MC. Genetic and epigenetic insights into uveal melanoma. Clin Genet. 2018; 93: 952-61.

[32]

Ye M, Hu D, Tu L, Zhou X, Lu F, Wen B, et al. Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells. Invest Ophthalmol Vis Sci. 2008; 49: 497-504.

[33]

Topcu-Yilmaz P, Kiratli H, Saglam A, Söylemezoglu F, Hascelik G. Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma. Melanoma Res. 2010; 20: 126-32.

[34]

Komatsubara KM, Manson DK, Carvajal RD. Selumetinib for the treatment of metastatic uveal melanoma: past and future perspectives. Future Oncol. 2016; 12: 1331-44.

[35]

O’Donnell JS, Massi D, Teng MWL, Mandala M. PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. Semin Cancer Biol. 2018; 48: 91-103.

[36]

Yan F, Liao R, Farhan M, Wang T, Chen J, Wang Z, et al. Elucidating the role of the FoxO3a transcription factor in the IGF-1-induced migration and invasion of uveal melanoma cancer cells. Biomed Pharmacother. 2016; 84: 1538-50.

[37]

Chen Y, Liu X, Wang H, Liu S, Hu N, Li X. Akt Regulated Phosphorylation of GSK-3β/Cyclin D1, p21 and p27 Contributes to Cell Proliferation Through Cell Cycle Progression From G1 to S/G2M Phase in Low-Dose Arsenite Exposed HaCat Cells. Front Pharmacol. 2019; 10: 1176.

[38]

Geng Y, Geng Y, Liu X, Chai Q, Li X, Ren T, et al. PI3K/AKT/mTOR pathway-derived risk score exhibits correlation with immune infiltration in uveal melanoma patients. Front Oncol. 2023; 13: 1167930.

[39]

Werneburg N, Gores GJ, Smoot RL. The Hippo Pathway and YAP Signaling: Emerging Concepts in Regulation, Signaling, and Experimental Targeting Strategies With Implications for Hepatobiliary Malignancies. Gene Expr. 2020; 20: 67-74.

[40]

Souto EB, Zielinska A, Luis M, Carbone C, Martins-Gomes C, Souto SB, et al. Uveal melanoma: physiopathology and new in situ-specific therapies. Cancer Chemother Pharmacol. 2019; 84: 15-32.

[41]

Feng X, Arang N, Rigiracciolo DC, Lee JS, Yeerna H, Wang Z, et al. A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK. Cancer Cell. 2019; 35: 457-72.e5.

[42]

Feng X, Degese MS, Iglesias-Bartolome R, Vaque JP, Molinolo AA, Rodrigues M, et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell. 2014; 25: 831-45.

[43]

Brouwer NJ, Konstantinou EK, Gragoudas ES, Marinkovic M, Luyten GPM, Kim IK, et al. Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin. Invest Ophthalmol Vis Sci. 2021; 62: 3.

[44]

Knudsen ES, Nambiar R, Rosario SR, Smiraglia DJ, Goodrich DW, Witkiewicz AK. Pan-cancer molecular analysis of the RB tumor suppressor pathway. Commun Biol. 2020; 3: 158.

[45]

Wu T, Wu L. The Role and Clinical Implications of the Retinoblastoma (RB)-E2F Pathway in Gastric Cancer. Front Oncol. 2021; 11: 655630.

[46]

Meng F, Yuan Y, Ren H, Yue H, Xu B, Qian J. SUMOylation regulates Rb hyperphosphorylation and inactivation in uveal melanoma. Cancer Sci. 2022; 113: 622-33.

[47]

Russo D, Di Crescenzo RM, Broggi G, Merolla F, Martino F, Varricchio S, et al. Expression of P16INK4a in Uveal Melanoma: New Perspectives. Front Oncol. 2020; 10: 562074.

[48]

Rahgozar M, Pazokitoroudi H, Bakhtiarian A, Djahanguiri B. Diazoxide, a KATP opener, accelerates restitution of ethanol or indomethacin-induced gastric ulceration in rats independent of polyamines. J Gastroenterol Hepatol. 2001; 16: 290-6.

[49]

Habibey R, Ajami M, Ebrahimi SA, Hesami A, Babakoohi S, Pazoki-Toroudi H. Nitric oxide and renal protection in morphine-dependent rats. Free Radic Biol Med. 2010; 49: 1109-18.

[50]

Marei HE, Althani A, Afifi N, Hasan A, Caceci T, Pozzoli G, et al. p53 signaling in cancer progression and therapy. Cancer Cell Int. 2021; 21: 703.

[51]

Hernández Borrero LJ, El-Deiry WS. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochim Biophys Acta Rev Cancer. 2021; 1876: 188556.

[52]

Lahalle A, Lacroix M, De Blasio C, Cissé MY, Linares LK, Le Cam L. The p53 Pathway and Metabolism: The Tree That Hides the Forest. Cancers (Basel). 2021; 13: 133.

[53]

Hajkova N, Hojny J, Nemejcova K, Dundr P, Ulrych J, Jirsova K, et al. Germline mutation in the TP53 gene in uveal melanoma. Sci Rep. 2018; 8: 7618.

[54]

Johansson PA, Brooks K, Newell F, Palmer JM, Wilmott JS, Pritchard AL, et al. Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours. Nat Commun. 2020; 11: 2408.

[55]

Liu H, Zhou M. Evaluation of p53 gene expression and prognosis characteristics in uveal melanoma cases. Onco Targets Ther. 2017; 10: 3429-34.

[56]

Bellini L, Strub T, Habel N, Pandiani C, Marchetti S, Martel A, et al. Endoplasmic reticulum stress mediates resistance to BCL-2 inhibitor in uveal melanoma cells. Cell Death Discov. 2020; 6: 22.

[57]

Ajami M, Eghtesadi S, Razaz JM, Kalantari N, Habibey R, Nilforoushzadeh MA, et al. Expression of Bcl-2 and Bax after hippocampal ischemia in DHA + EPA treated rats. Neurol Sci. 2011; 32: 811-8.

[58]

Banimohammad M, Ravaei H, Khalafi P, Javdan G, Ayatollahi SA, Davoodi SH. Change in total anti-oxidant capacity (TAC) of tissue, a new method for improving dermal wound healing. SJKU. 2019; 24: 96-109.

[59]

Sun Y, Tran BN, Worley LA, Delston RB, Harbour JW. Functional analysis of the p53 pathway in response to ionizing radiation in uveal melanoma. Invest Ophthalmol Vis Sci. 2005; 46: 1561-4.

[60]

Yang ZK, Yang JY, Xu ZZ, Yu WH. DNA Methylation and Uveal Melanoma. Chin Med J (Engl). 2018; 131: 845-51.

[61]

Onken MD, Worley LA, Harbour JW. A metastasis modifier locus on human chromosome 8p in uveal melanoma identified by integrative genomic analysis. Clin Cancer Res. 2008; 14: 3737-45.

[62]

Ehlers JP, Worley L, Onken MD, Harbour JW. DDEF1 is located in an amplified region of chromosome 8q and is overexpressed in uveal melanoma. Clin Cancer Res. 2005; 11: 3609-13.

[63]

Laurent C, Valet F, Planque N, Silveri L, Maacha S, Anezo O, et al. High PTP4A3 phosphatase expression correlates with metastatic risk in uveal melanoma patients. Cancer Res. 2011; 71: 666-74.

[64]

Asnaghi L, Ebrahimi KB, Schreck KC, Bar EE, Coonfield ML, Bell WR, et al. Notch signaling promotes growth and invasion in uveal melanoma. Clin Cancer Res. 2012; 18: 654-65.

[65]

Carvajal RD, Schwartz GK, Tezel T, Marr B, Francis JH, Nathan PD. Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol. 2017; 101: 38-44.

[66]

Smit KN, Jager MJ, de Klein A, Kiliҫ E. Uveal melanoma: Towards a molecular understanding. Prog Retin Eye Res. 2020; 75: 100800.

[67]

Mirzaei-Parsa MJ, Najafabadi MRH, Haeri A, Zahmatkeshan M, Ebrahimi SA, Pazoki-Toroudi H, et al. Preparation, characterization, and evaluation of the anticancer activity of artemether-loaded nano-niosomes against breast cancer. Breast Cancer. 2020; 27: 243-51.

[68]

Chen MX, Liu YM, Li Y, Yang X, Wei WB. Elevated VEGF-A & PLGF concentration in aqueous humor of patients with uveal melanoma following Iodine-125 plaque radiotherapy. Int J Ophthalmol. 2020; 13: 599-605.

[69]

Mabeta P. Paradigms of vascularization in melanoma: Clinical significance and potential for therapeutic targeting. Biomed Pharmacother. 2020; 127: 110135.

[70]

Lattanzio L, Tonissi F, Torta I, Gianello L, Russi E, Milano G, et al. Role of IL-8 induced angiogenesis in uveal melanoma. Invest New Drugs. 2013; 31: 1107-14.

[71]

Pazoki-Toroudi H, Nassiri-Kashani M, Tabatabaie H, Ajami M, Habibey R, Shizarpour M, et al. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. J Dermatolog Treat. 2010; 21: 212-6.

[72]

Ajami M, Davoodi SH, Habibey R, Namazi N, Soleimani M, Pazoki-Toroudi H. Effect of DHA+EPA on oxidative stress and apoptosis induced by ischemia-reperfusion in rat kidneys. Fundam Clin Pharmacol. 2013; 27: 593-602.

[73]

Toroudi HP, Rahgozar M, Bakhtiarian A, Djahanguiri B. Potassium channel modulators and indomethacin-induced gastric ulceration in rats. Scand J Gastroenterol. 1999; 34: 962-6.

[74]

Pazoki-Toroudi H, Nilforoushzadeh MA, Ajami M, Jaffary F, Aboutaleb N, Nassiri-Kashani M, et al. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutan Ocul Toxicol. 2011; 30: 286-91.

[75]

Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res. 2008; 14: 6735-41.

[76]

Singh S, Nannuru KC, Sadanandam A, Varney ML, Singh RK. CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion. Br J Cancer. 2009; 100: 1638-46.

[77]

Javedan G, Shidfar F, Davoodi SH, Ajami M, Gorjipour F, Sureda A, et al. Conjugated linoleic acid rat pretreatment reduces renal damage in ischemia/reperfusion injury: Unraveling antiapoptotic mechanisms and regulation of phosphorylated mammalian target of rapamycin. Mol Nutr Food Res. 2016; 60: 2665-77.

[78]

Habibey R, Pazoki-Toroudi H. Morphine dependence protects rat kidney against ischaemia-reperfusion injury. Clin Exp Pharmacol Physiol. 2008; 35: 1209-14.

[79]

Bronkhorst IH, Vu TH, Jordanova ES, Luyten GP, Burg SH, Jager MJ. Different subsets of tumor-infiltrating lymphocytes correlate with macrophage influx and monosomy 3 in uveal melanoma. Invest Ophthalmol Vis Sci. 2012; 53: 5370-8.

[80]

Maat W, Ly LV, Jordanova ES, de Wolff-Rouendaal D, Schalij-Delfos NE, Jager MJ. Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma. Invest Ophthalmol Vis Sci. 2008; 49: 505-10.

[81]

Herwig MC, Grossniklaus HE. Role of macrophages in uveal melanoma. Expert Rev Ophthalmol. 2011; 6: 405-7.

[82]

Caporarello N, Olivieri M, Cristaldi M, Rusciano D, Lupo G, Anfuso CD. Melanogenesis in uveal melanoma cells: Effect of argan oil. Int J Mol Med. 2017; 40: 1277-84.

[83]

Martin M, Maßhöfer L, Temming P, Rahmann S, Metz C, Bornfeld N, et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet. 2013; 45: 933-6.

[84]

Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010; 330: 1410-3.

[85]

Drabarek W, van Riet J, Nguyen JQN, Smit KN, van Poppelen NM, Jansen R, et al. ; On Behalf Of The Rotterdam Ocular Melanoma Study Group. Identification of Early-Onset Metastasis in SF3B1 Mutated Uveal Melanoma. Cancers (Basel). 2022; 14: 846.

[86]

Yavuzyigitoglu S, Drabarek W, Smit KN, van Poppelen N, Koopmans AE, Vaarwater J, et al. ; Rotterdam Ocular Melanoma Study Group. Correlation of Gene Mutation Status with Copy Number Profile in Uveal Melanoma. Ophthalmology. 2017; 124: 573-5.

[87]

Ehlers JP, Harbour JW. NBS1 expression as a prognostic marker in uveal melanoma. Clin Cancer Res. 2005; 11: 1849-53.

[88]

Sulkowska M, Famulski W, Bakunowicz-Lazarczyk A, Chyczewski L, Sulkowski S. Bcl-2 expression in primary uveal melanoma. Tumori. 2001; 87: 54-7.

[89]

Coupland SE, Bechrakis N, Schüler A, Anagnostopoulos I, Hummel M, Bornfeld N, et al. Expression patterns of cyclin D1 and related proteins regulating G1-S phase transition in uveal melanoma and retinoblastoma. Br J Ophthalmol. 1998; 82: 961-70.

[90]

Moulin AP, Clément G, Bosman FT, Zografos L, Benhattar J. Methylation of CpG island promoters in uveal melanoma. Br J Ophthalmol. 2008; 92: 281-5.

[91]

Uner OE, See TRO, Szalai E, Grossniklaus HE, Stålhammar G. Estimation of the timing of BAP1 mutation in uveal melanoma progression. Sci Rep. 2021; 11: 8923.

[92]

Matatall KA, Agapova OA, Onken MD, Worley LA, Bowcock AM, Harbour JW. BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma. BMC Cancer. 2013; 13: 371.

[93]

Sowa ME, Bennett EJ, Gygi SP, Harper JW. Defining the human deubiquitinating enzyme interaction landscape. Cell. 2009; 138: 389-403.

[94]

Misaghi S, Ottosen S, Izrael-Tomasevic A, Arnott D, Lamkanfi M, Lee J, et al. Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1. Mol Cell Biol. 2009; 29: 2181-92.

[95]

Aliabadi F, Sohrabi B, Mostafavi E, Pazoki-Toroudi H, Webster TJ. Ubiquitin-proteasome system and the role of its inhibitors in cancer therapy. Open Biol. 2021; 11: 200390.

[96]

Zhang L, He X, Li F, Pan H, Huang X, Wen X, et al. The miR-181 family promotes cell cycle by targeting CTDSPL, a phosphatase-like tumor suppressor in uveal melanoma. J Exp Clin Cancer Res. 2018; 37: 15.

[97]

Liu J, Shi W, Wu C, Ju J, Jiang J. miR-181b as a key regulator of the oncogenic process and its clinical implications in cancer (Review). Biomed Rep. 2014; 2: 7-11.

[98]

Yan D, Dong XD, Chen X, Yao S, Wang L, Wang J, et al. Role of microRNA-182 in posterior uveal melanoma: regulation of tumor development through MITF, BCL2 and cyclin D2. PLoS One. 2012; 7: e40967.

[99]

Yang C, Wei W. The miRNA expression profile of the uveal melanoma. Sci China Life Sci. 2011; 54: 351-8.

[100]

Worley LA, Long MD, Onken MD, Harbour JW. Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling. Melanoma Res. 2008; 18: 184-90.

[101]

Pazoki-Toroudi HR, Ajami M, Habibey R. Pre-medication and renal pre-conditioning: a role for alprazolam, atropine, morphine and promethazine. Fundam Clin Pharmacol. 2010; 24: 189-98.

[102]

Shoorei H, Banimohammad M, Kebria MM, Afshar M, Taheri MM, Shokoohi M, et al. Hesperidin improves the follicular development in 3D culture of isolated preantral ovarian follicles of mice. Exp Biol Med (Maywood). 2019; 244: 352-61.

[103]

Yang JY, Li Y, Wang Q, Zhou WJ, Yan YN, Wei WB. MicroRNA-145 suppresses uveal melanoma angiogenesis and growth by targeting neuroblastoma RAS viral oncogene homolog and vascular endothelial growth factor. Chin Med J (Engl). 2020; 133: 1922-9.

[104]

Smit KN, Boers R, Vaarwater J, Boers J, Brands T, Mensink H, et al. Genome-wide aberrant methylation in primary metastatic UM and their matched metastases. Sci Rep. 2022; 12: 42.

[105]

Charlet J, Tomari A, Dallosso AR, Szemes M, Kaselova M, Curry TJ, et al. Genome-wide DNA methylation analysis identifies MEGF10 as a novel epigenetically repressed candidate tumor suppressor gene in neuroblastoma. Mol Carcinog. 2017; 56: 1290-301.

[106]

Huang M, Weiss WA. Neuroblastoma and MYCN. Cold Spring Harb Perspect Med. 2013; 3: a014415.

[107]

Memon A, Lee WK. KLF10 as a Tumor Suppressor Gene and Its TGF-β Signaling. Cancers (Basel). 2018; 10: 161.

[108]

Chokhachi Baradaran P, Kozovska Z, Furdova A, Smolkova B. Targeting Epigenetic Modifications in Uveal Melanoma. Int J Mol Sci. 2020; 21: 5314.

[109]

Pašalić D, Nikuševa-Martić T, Sekovanić A, Kaštelan S. Genetic and Epigenetic Features of Uveal Melanoma-An Overview and Clinical Implications. Int J Mol Sci. 2023; 24: 12807.

[110]

Slominski AT, Brożyna AA, Zmijewski MA, Jóźwicki W, Jetten AM, Mason RS, et al. Vitamin D signaling and melanoma: role of vitamin D and its receptors in melanoma progression and management. Lab Invest. 2017; 97: 706-24.

PDF (2842KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉